Vericel Corp VCEL

US Biotechnology

$45.96 ▼ -3.47% ($-1.65)

⬇️ Below Yest. Low

Open $46.97

Prev Close $47.61

Day Range $45.17 – $47.11

52W Range $28.95 – $49.32

Market Cap $2.35B

P/E (TTM) 112.10

Beta 1.07

EPS (TTM) $0.36

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1997-02-04
Shares Out.	51,070,000
Website	vcel.com/ ↗
Phone	17349305555
Employees	398
Revenue	$68.4M
Gross Profit	$49.3M
Net Income	-$6.3M
Free Cash Flow	$47.5M
Total Assets	$485.6M
Total Liabilities	$129.4M
Equity	$356.2M

About Vericel Corp

Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Vericel Corp is a publicly traded company under the ticker symbol VCEL on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.